Block Grant R43CA124006

Summary Columbia University's Health Sciences Division received a $727,904 Cooperative Agreement award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) on August 11, 2025, for research on engineered probiotic bacteria to prevent and intercept colorectal cancer (CRC). The award supports a two-phase UG3/UH3 project designed to develop and characterize engineered strains of Escherichia coli Nissle 1917 (ECN) that selectively colonize precancerous lesions...

This $399,187 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Virginia Commonwealth University to study the role of ATG16L1 isoforms in colorectal cancer health disparities. The key objectives are to: 1) Determine whether the ATG16L1 T300T isoform, which is more predominant in African Americans, promotes more aggressive colorectal tumor growth and metastasis compared to the A300A isoform found more in...

This $627,422 Project Grant award from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program supports research by the Regents of the University of Michigan to engineer commensal bacteria that can neutralize the colibactin genotoxin produced by certain gut bacteria associated with increased colorectal cancer risk. The key products and services to be delivered under this 5-year grant include: 1) Further optimization of the surface display of the anti-toxin...

Federal Grant Award Summary Xgenomes Corp. received a $399,816 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) beginning September 1, 2025, with completion scheduled for August 31, 2026. The company is developing a novel circulating tumor DNA (ctDNA) analysis platform that directly measures both genetic mutations and DNA methylation changes with accuracy approximately 100 times greater than current next-generation...

Federal Grant Award Summary The National Cancer Institute (NCI), under its Cancer Detection and Diagnosis Research Program (CFDA 93.394), awarded Cedars-Sinai Medical Center a Project Grant of $662,610 on April 1, 2026, for research extending through March 31, 2031. The award supports the development and validation of universal methylated circulating tumor DNA (ctDNA) markers for minimal residual disease (MRD) detection and therapy response prediction in colorectal cancer. This research...

This Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute provides $582,100 to East Carolina University to support research on the role of mitochondrial complex I deficiency in colorectal cancer (CRC) tumor growth and progression. The research aims to elucidate how accumulated mitochondrial DNA mutations that disrupt complex I activity can paradoxically support CRC tumorigenesis, despite the general requirement for...

This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...

This $388,673 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development of novel statistical methods to identify and evaluate predictive biomarkers for targeted cancer therapies using data from non-randomized Phase II clinical trials. The key products of this 2-year project, led by the University of Kentucky Research Foundation, include: Novel semiparametric statistical models to identify and...

Federal Grant Award Summary The University of Virginia received a $192,888 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective September 1, 2025, through August 31, 2028. This award supports a novel research initiative designed to identify causal genetic variants associated with colorectal cancer (CRC) risk and elucidate their mechanistic effects through the use of normal colon organoids. The project addresses a critical gap in...

Federal Grant Award Summary Endure Biotherapeutics, Inc. received a $392,827 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria (ENB) as a novel therapeutic approach for familial adenomatous polyposis (FAP). The award, effective August 5, 2025, with completion targeted for July 31, 2026, supports the advancement of the company's platform technology that engineers native gut bacteria to express...